T1R2-T1R3 is a heteromeric receptor that binds sugars, high potency sweeteners, and sweet taste blockers. In rodents, T1R2-T1R3 is largely responsible for transducing sweet taste perception. T1R2-T1R3 is also expressed in non-taste tissues, and a growing body of evidence suggests that it helps regulate glucose and lipid metabolism. It was previously shown that clofibric acid, a blood lipid-lowering drug, binds T1R2-T1R3 and inhibits its activity in vitro. The purpose of this study was to determine whether clofibric acid inhibits sweetness perception in humans and is, therefore, a T1R2-T1R3 antagonist in vivo. Fourteen participants rated the sweetness intensity of 4 sweeteners (sucrose, sucralose, Na cyclamate, acesulfame K) across a broad range of concentrations. Each sweetener was prepared in solution neat and in mixture with either clofibric acid or lactisole. Clofibric acid inhibited sweetness of every sweetener. Consistent with competitive binding, inhibition by clofibric acid was diminished with increasing sweetener concentration. This study provides in vivo evidence that the lipid-lowering drug clofibric acid inhibits sweetness perception and is, therefore, a T1R carbohydrate receptor inhibitor. Our results are consistent with previous in vitro findings. Given that T1R2-T1R3 may in part regulate glucose and lipid metabolism, future studies should investigate the metabolic effects of T1R inhibition.
Introduction
In vitro functional expression and mouse knock-out data suggest that sweet taste perception is chiefly transduced by T1R2-T1R3, a heteromeric carbohydrate receptor of the 7 transmembrane family, Class C (Nelson et al. 2001; Li et al. 2002) . T1R2-T1R3 is activated by several mono-and disaccharides as well as high potency sweeteners (HPSs) (Cui et al. 2006) . In humans it is inhibited by sodium lactisole, an inverse agonist which binds the transmembrane domain of human-T1R3 (Jiang et al. 2005; . A growing body of evidence shows that T1R2-T1R3 is expressed in tissues throughout the body and that it serves physiological roles in glucose metabolism, insulin secretion, lipid metabolism, adipocyte function, and reproductive health Mosinger et al. 2013; Smith et al. 2016) .
Several studies have established a role for T1R2-T1R3 in glucose metabolism. In vitro, HPSs induce the secretion of GLP-1 by intestinal L-cells (Jang et al. 2007; Margolskee et al. 2007 ). High potency sweeteners upregulate the expression of glucose transporters in the intestine (Mace et al. 2007; Moran et al. 2010) . T1R2-T1R3 is also expressed in pancreatic beta cells and in vitro stimulation with a HPS induces insulin release (Nakagawa et al. 2009; Nakagawa et al. 2013) . Several clinical studies have shown that a HPS preload alters the plasma insulin, glucose, and incretin responses to an oral glucose load, despite the fact that HPS are not by themselves insulinogenic, neither do they contain glucose nor any calories of note (Brown et al. 2009 (Brown et al. , 2012 Pepino et al. 2013; Temizkan et al. 2015) .
T1R2-T1R3 is also expressed in adipocytes (Masubuchi et al. 2013) . Stimulation with HPSs alters adipogenesis and lipolysis in vitro (Masubuchi et al. 2013; Simon et al. 2013) . When fed an obesogenic diet, T1R2 KO mice and T1R3 KO mice are protected against fat mass gain (Simon et al. 2014; Smith et al. 2016) . This may be due to oral perceptual influences on nutrient utilization and metabolism (Glendinning et al. 2012 ), or to a reduced ability of adipocytes to sense and transport glucose internally (Smith et al. 2016) .
Although the relationships between T1R2-T1R3 agonists and human physiology have come under scrutiny, the physiological effects of T1R2-T1R3 antagonists are less clearly understood. Genetic knock-out studies represent the ultimate loss of function of the T1R2-T1R3 receptors, but pharmacological inhibition may have similar, albeit less potent, effects on metabolism. It has been shown that the T1R3 inhibitor sodium lactisole increases plasma glucose 'area under the curve' (AUC) response to a glucose load (Gerspach et al. 2011 ). This effect is consistent with reduced stimulation of insulin by T1Rs (Jiang et al. 2005; Hamano et al. 2015) . Whether other sweet taste inhibitors have similar physiological effects on human physiology is unclear.
Lactisole is structurally a phenoxy propionic acid, and so has molecular similarity to other members of this class, including the phenoxy herbicides and the metabolic fibrate drugs. The fibrates are a class of "plasma lipid lowering" drug which are presumed to exert their effects by binding and inhibiting the nuclear receptor proteins, the peroxisome proliferator-activated receptors (PPARs), especially PPAR-α (Lalloyer and Staels 2010) . The PPARs form heterodimers with the retinoid X receptors (RXR) to regulate gene expression and modulate metabolism, among many other physiological functions (Staels et al. 1998; Lalloyer and Staels 2010) . These heterodimers are the presumed mechanism for how fibrate drugs are able to lower plasma lipids in patients. In addition to binding PPARs, fibrate drugs behave pharmacologically in vitro like the T1R2-T1R3 inhibitor lactisole and bind the transmembrane domain of human T1R3 (Maillet et al. 2009 ). Curiously, fibrates bind PPARs and T1R3 with a similar affinity (Maillet et al. 2009 ).
Fibrates have clinical physiological effects on metabolism and are known to bind the sweet taste receptor T1R2-T1R3. This observation raises the question of whether fibrates might exert some of their physiological effects through their actions on T1R2-T1R3. Thus, we wished to determine whether fibrates inhibit T1R2-T1R3 in vivo in humans. As one measure of this effect, we sought in the present study to determine whether the fibrate drug, clofibric acid, inhibits perception of sweetness in humans and is, therefore, a T1R2-T1R3 receptor antagonist in conscious behaving humans. We tested 4 sweeteners (sucrose, sucralose, acesulfame-K, and Na cyclamate) in mixture with either clofibric acid or the positive control sweet taste inhibitor, sodium lactisole.
Methods

Subjects
Fourteen adult subjects (5 males, 9 females) aged between 18 and 29 years were paid to participate after providing their informed consent on Rutgers University's Institutional Review Board (IRB) approved forms. All participants were from Rutgers University and the surrounding community. Each subject participated in 6 sessions. They were asked not to eat, drink, or smoke 1 h prior to each session. This protocol complies with the Declaration of Helsinki for Medical Research involving Human Subjects and the study was approved by the Institutional Review Board at Rutgers University.
Training
Subjects were trained in the use of a general Labeled Magnitude Scale (gLMS) following standard published procedures (Green et al. 1993) . The top of the scale was described as the strongest imaginable sensation of any kind (Bartoshuk et al. 2004 ). This gLMS required participants to rate the perceived intensity along a vertical axis lined with the following adjectives: barely detectable, weak, moderate, strong, very strong, and strongest imaginable. The adjectives are spaced semi-logarithmically, based upon experimentally determined intervals to yield ratio quality data. The subjects were shown both adjectives and numbers on the scale.
Stimuli
The sweet taste stimuli were sucrose (ranging in concentration from 0.0292 to 1.64 M), sucralose (7.95 × 10 −6 to 7.95 × 10 −2 M), acesulfame potassium (1.57 × 10 − 5 to 0.15 M), and sodium cyclamate (4.97 × 10 −4 to 0.496 M). Concentrations increased in quarter-and semi-logarithmic increments and captured asymptotic sweetness intensity. The sweet taste inhibitors used were 1.37 mM sodium lactisole and 1.37 mM clofibric acid. Each sweet compound was presented neat and in combination with each inhibitor. Clofibric acid was neutralized with sodium hydroxide to match the pH of the neat solution.
Aqueous solutions were prepared every other day with Millipore filtered water and stored in amber glass at 4 °C. All solutions were removed from refrigerator and allowed to rise to room temperature for at least 1 h prior to tasting. All solutions were fully dissolved and there were no visible signs of undissolved solids or precipitation from solutions.
Stimulus delivery
Sample presentation was randomized using a random integer generator (random.org) and 10 ml of each solution was presented in 30 ml polyethylene medicine cups (Dynarex) on a numbered tray. Each session consisted of 2 trials with an interstimulus interval of 30 s and a 5-min interval between trials. For each sample, subjects held 10 ml of solution in the mouth for 5 s and rated the taste qualities (sweet, bitter, salty, sour, savory) and intensity on a gLMS before expectorating. Subjects separately rated each taste quality on a gLMS. After expectorating, subjects rinsed with Millipore water 4 times during the interstimulus interval.
Statistical analysis
For each of the 4 sweeteners studied, 2-way repeated measures analysis of variance (ANOVA) was used to analyze the effects of stimulus (sweetener neat, sweetener + lactisole, sweetener + clofibric acid). Post hoc Tukey's honestly significant difference (HSD) tests were used to analyze differences among responses.
Results
Clofibric acid inhibited the sweetness elicited by all of the sweeteners studied (Figure 1) . The main effect of stimulus was significant for sucrose (F 2,26 = 6.4; P < 0.01), sucralose (F 2,26 = 8.4; P < 0.01), acesulfame K (F 2,26 = 9.1; P < 0.01), and Na cyclamate (F 2,26 = 50.2; P < 0.01). There was a significant interaction of stimulus and concentration for each sweetener, indicating that the efficacy of inhibitor was affected by concentration. Consistent with competitive binding, the inhibition by clofibrate was diminished with increasing concentration of sucrose and cyclamate. However, in the case of sucralose and acesulfame K, inhibition was not completely diminished at maximum sweetener concentration.
Clofibric acid and lactisole were similar in terms of inhibitory potency. For sucrose, however, the effect of lactisole was greater than the effect of clofibric acid (P < 0.05). There were no other significant differences in main effects between clofibric acid and lactisole, although clofibric acid tended to be a more potent inhibitor of sweet taste elicited by acesulfame K ( Figure 1D ).
There were no significant differences in bitter, salty, sour, or savory qualities between neat and inhibited conditions (not shown). Sucralose and acesulfame K elicited weak bitterness at high concentrations in the neat and inhibited conditions in some subjects. There were no differences in bitterness (P > 0.05). Sucrose elicited only sweetness in the neat and inhibited conditions.
Discussion
These data show that clofibric acid inhibits sweet taste elicited by four different T1R2-T1R3 agonists: a sugar and 3 HPSs. This is consistent with previous findings that clofibric acid binds a transmembrane domain of T1R2-T1R3 (Maillet et al. 2009 ). These data also further support the hypothesis that T1R2-T1R3 is largely responsible for transducing sweet taste in humans.
Although clofibric acid and lactisole inhibited sweet taste, neither compound abolished sweet taste completely. Also, sweetness inhibition was overcome at higher concentrations of sucrose and cyclamate. This observation is consistent with competitive inhibition, similar to previously studied sweet taste inhibitors (Schiffman et al. 1999; Winnig et al. 2007 ). The highest molar concentrations of sucrose and cyclamate used in this study were greater than those of acesulfame K and sucralose. It is unclear whether inhibition of acesulfame K and sucralose sweetness would continue at higher levels of these sweeteners or whether sweetness would return to uninhibited high levels.
As previously reported (Antenucci and Hayes 2014) , high levels of sucralose (25 and 79 mM) and acesulfame K (50 and 150 mM) elicited bitter taste in some participants. In mixtures of sweet and bitter compounds, inhibition of sweetness has been shown to enhance bitterness (Lawless 1979) . However, despite reducing sweetness from sucralose and acesulfame K, neither inhibitor affected ratings for bitter, sour, salty, or savory taste qualities. It is possible that some participants conflated bitterness with metallic tastes or other off tastes that we did not measure.
Clofibric acid only modestly inhibited sweet taste from sucrose relative to the effects of lactisole. This finding could be explained by non-T1R3 mediated sweet taste (Damak et al. 2003) . K ATP channels are part of a metabolic signaling pathway and are expressed in many taste cells and may contribute to depolarization of these cells and activation of downstream signaling events (Merigo et al. 2011; Yee et al. 2011) . In T1R3 knockout mice, nerve responses to glucose were diminished but not abolished (Damak et al. 2003) , indicating residual signaling from sugars in mice.
Subjects in this study reported sweet water taste after expectorating either lactisole or clofibric acid (not shown). Previous studies have shown that lactisole elicits a sweet water-taste, most likely because it is a T1R2-T1R3 inverse agonist . Our finding that clofibric acid elicits a similar rebound effect suggests that, like lactisole, it too is an inverse agonist of T1R2-T1R3. Concentration-intensity functions were determined for each sweetener neat, in admixture with lactisole, and in admixture with clofibric acid. The main effect of stimulus was significant for every sweetener studied. Main effects of stimuli (sweetener neat, sweetener + lactisole, sweetener + clofibric acid) were determined using 2-way repeated measures analysis of variance (ANOVA). Pairwise differences were determined using post hoc Tukey HSD tests (n = 14). Each subject was tested in sextuplicate. Letters denote significant differences (P < 0.05) between stimuli. * denotes significant difference between neat and lactisole. † denotes significant difference between neat and clofibric acid. ‡ denotes significant differences between lactisole and clofibric acid.
Clofibric acid is used pharmacologically to lower blood cholesterol and triglycerides. Treatment with clofibric acid reduces hepatic lipid deposition (Ye et al. 2001) , as well as fasting and postprandial glycemia (Enger et al. 1977; Ferrari et al. 1977; Ratzmann et al. 1983 ). Clofibric acid is hypothesized to act through peroxisome proliferator-activated receptor α (PPARα) activation (Staels et al. 1998) . PPARα is a transcription factor that upregulates genes responsible for fatty acid uptake, beta oxidation, lipolysis, and lipoprotein synthesis (Lalloyer and Staels 2010) . Although clofibric acid is known to bind PPARα, it is not known whether all of its physiological effects are due exclusively to PPARα agonism.
The effects of chronic treatment with clofibric acid share some overlap with the effects of T1R2 and T1R3 ablation. Similar to clofibric acid treatment, T1R ablation alters glucose and lipid metabolism Glendinning et al. 2012; Simon et al. 2014; Smith et al. 2016) . T1R2 knockout animals are protected against diet induced obesity, hepatic lipid deposition, and hypersinsulinemia (Simon et al. 2014; Smith et al. 2016) . Like the T1R2 knockout, T1R3 knockout animals are protected against diet induced weight gain and fat mass gain, independent of energy intake (Glendinning et al. 2012) .
T1R knockouts may be protected against lipid accumulation because of impaired assimilation of dietary carbohydrate. T1R2-T1R3 is expressed in many tissues throughout the body, including the intestine , liver (Taniguchi 2004) , pancreas (Taniguchi 2004) , adipocytes (Masubuchi et al. 2013) , and brain (Ren et al. 2009 ). T1R2-T1R3 agonists enhance intestinal glucose absorption ), incretin response (Brown et al. 2009 ), insulin secretion (Pepino et al. 2013) , and adipocyte differentiation (Masubuchi et al. 2013) . Sodium lactisole, a T1R2-T1R3 inhibitor, has been shown to lower insulin secretion and GLP-1 secretion in vitro (Jang et al. 2007; Nakagawa 2011) and in vivo (Gerspach et al. 2011) . Given that clofibric acid inhibits T1R2-T1R3, it is possible that its metabolic effects may be due, in part, to T1R inhibition.
These data show that clofibric acid inhibits sweet taste perception and is thus not only a T1R2-T1R3 receptor inhibitor in vitro but appears to inhibit it in vivo as well. These perceptual data are supported by previous findings that clofibric acid binds selectively and inhibits T1R3 in vitro. Future studies should investigate the metabolic effects of T1R inhibition to determine the degree to which fibrates and other T1R inhibitors influence dyslipidemias and cholesterol.
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